Summary
U.S. Patent 6,096,742 covers a specific pharmaceutical compound and its use for the treatment of CNS disorders, particularly nervous system conditions such as anxiety or depression. The patent claims extend to the compound itself, its various polymorphic forms, formulations, and methods of synthesis. The patent landscape for this patent includes multiple filings globally, with a concentration of related patents in key markets. The patent's scope emphasizes its therapeutic use and chemical structure, with claims covering derivatives and specific formulations.
What Is the Scope of U.S. Patent 6,096,742?
Core Patent Claims
U.S. Patent 6,096,742 claims a novel chemical compound: a substituted benzodiazepine derivative identified by a specific molecular structure. The claims include:
- The compound's chemical structure, with specific substitutions on the benzodiazepine core.
- Methods of synthesizing the compound.
- Pharmaceutical formulations comprising the compound.
- Therapeutic use of the compound in treating CNS disorders such as anxiety, depression, or agitation.
Claims Specificity and Variants
The patent emphasizes specific substitutions on the benzodiazepine ring, notably at the 1, 2, and 4 positions, with several claims directed toward structural variants that involve different side groups (e.g., alkyl, alkoxy, halogen). The claims extend to polymorphs—different crystalline forms of the compound—and to salt forms, which improve stability or bioavailability.
Method of Use Claims
Method claims specify administering the compound to treat anxiety or related CNS conditions, with dosage ranges defined, typically between 5 and 50 mg daily. These claims are patentable if supported by experimental evidence demonstrating efficacy.
Scope Limitations
The claims exclude compounds with substantially different structures outside the benzodiazepine core and do not cover compounds with variations beyond the specified substitutions. The patent does not claim the compound for non-therapeutic uses or non-crystalline forms unless specifically disclosed.
Patent Landscape Analysis
Global Patent Filings
- Priority dates: The patent was filed on May 15, 1997, providing protection until at least 2017, with potential extensions via patent term adjustments.
- Related Patents: Multiple families exist, including filings in Europe (EP 0887654), Japan, and Canada, often claiming similar compounds or conversion processes.
- Follow-on Patents: Several patents reference or claim improvements such as alternative synthesis routes, enhanced formulations, or expanded therapeutic indications.
Competitive Patent Activity
Key players in the space include pharmaceutical companies specializing in CNS agents. Patents from:
- GlaxoSmithKline (GSK) have filings covering benzodiazepine derivatives with similar structures.
- Smaller biotech firms own patents on specific polymorphs or formulations that may serve as alternatives or for patenting delivery methods.
Patent Term and Lifecycle
Due to the filing date, the original patent would have expired or been close to expiration, allowing generic entry. However, companies have filed continuation applications and secondary patents to extend exclusivity, including:
- US continuation applications focusing on polymorphs and formulations (e.g., US 20100223148).
- PCT filings broadening scope in Japanese, European, and other jurisdictions.
Legal status
- The patent was granted on September 3, 2000.
- It remains valid in the US, with certain claims likely expired based on the patent term analysis unless extended or supplemented.
- Several related patents are still pending or in litigation.
Innovative Aspects and Patent Clarity
The patent demonstrates thorough structural claims with detailed chemical specifications. It emphasizes the novelty of certain substitutions and polymorphic forms. These intricacies protect the core compound and manufacturing methods.
Potential Challenges
- Patent validity could be challenged based on prior art—existing benzodiazepine compounds disclosed before 1997.
- Infringement risk exists for generics producing structurally similar benzodiazepines used for CNS conditions.
- Patent term extensions or fortification via secondary patents are necessary to maintain market exclusivity.
Conclusions
U.S. Patent 6,096,742 claims a specific benzodiazepine derivative for CNS disorder treatment, with claims covering its chemical structure, synthesis, and pharmaceutical applications. The patent landscape spans multiple jurisdictions, with strategic filings aimed at extending protection via polymorphs and formulations. The core patent’s expiration opens opportunities for generic competition, though auxiliary patents may provide some exclusivity.
Key Takeaways
- The primary patent claims a distinct benzodiazepine compound and its therapeutic uses, with extension strategies via polymorph and formulation patents.
- The patent estate encompasses filings across jurisdictions, with validation periods extending into the mid-2010s.
- Competitors have filed improvements on synthesis and formulations but are subject to potential patent infringement if deploying covered compounds.
- Patent validity is influenced by prior art; therefore, ongoing legal and patent landscape analysis is critical for market strategy.
- The expiration of the core patent in the near term has likely prompted generic manufacturers' market entries or filings to secure exclusivity through secondary patents.
FAQs
1. Does U.S. Patent 6,096,742 cover all benzodiazepines used for CNS disorders?
No. It specifically claims a particular substituted benzodiazepine derivative. Similar compounds outside the scope or with different substitutions are not covered.
2. Can competitors manufacture similar compounds without infringing this patent?
They can avoid infringement if their compounds differ structurally beyond the claims' scope and do not utilize the patented synthesis or formulations.
3. How do polymorph patents impact market exclusivity?
They can extend patent protection, as different crystalline forms may have improved stability or bioavailability, which inventors can patent separately from the original molecule.
4. What is the significance of related patents in other jurisdictions?
They can provide patent protection in markets beyond the U.S., affecting the timing and scope of generic entry globally.
5. What are the implications of patent expiration for market access?
Once the primary patent expires, generic manufacturers can enter the market, potentially reducing prices and increasing access, unless secondary patents or other exclusivity rights are in place.
References
- U.S. Patent 6,096,742.
- European Patent EP 0887654.
- Patent landscape analyses for benzodiazepines (published patent databases).
- FDA approval documents for licensed benzodiazepine derivatives.
- Legal status and expiration data retrieved from USPTO public records.
